Charles Schwab
ABVX

Charles Schwab’s Abivax ABVX Stock Holding History

Charles Schwab’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$443K Buy
+3,321
New +$376K ﹤0.01% 3259

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Charles Schwab's ABVX Position: Q2 2026 in Review

Charles Schwab opened a new position in Abivax (ABVX) in Q2 2026: 3,321 shares worth $443K. The stake represents ﹤0.01% of the portfolio and ranks #3259 among its holdings.

302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Charles Schwab held 3,321 shares of Abivax worth $443K as of Q2 2026.
  • Abivax was a new Charles Schwab position in Q2 2026.
  • Abivax made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3259 holding.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.